CN109734813A - 一种嵌合抗原受体及其应用 - Google Patents
一种嵌合抗原受体及其应用 Download PDFInfo
- Publication number
- CN109734813A CN109734813A CN201910081590.8A CN201910081590A CN109734813A CN 109734813 A CN109734813 A CN 109734813A CN 201910081590 A CN201910081590 A CN 201910081590A CN 109734813 A CN109734813 A CN 109734813A
- Authority
- CN
- China
- Prior art keywords
- people
- cell
- intracellular region
- intracellular
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 88
- 230000003834 intracellular effect Effects 0.000 claims abstract description 100
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims abstract description 78
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims abstract description 78
- 230000027455 binding Effects 0.000 claims abstract description 35
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 13
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 13
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 230000000139 costimulatory effect Effects 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 76
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 68
- 239000000427 antigen Substances 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 230000019491 signal transduction Effects 0.000 claims description 18
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 13
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 12
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 12
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 7
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims description 6
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims description 6
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 5
- 238000009169 immunotherapy Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 4
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 102000017578 LAG3 Human genes 0.000 claims description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 claims description 3
- 102100027010 Toll-like receptor 1 Human genes 0.000 claims description 3
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 102100038077 CD226 antigen Human genes 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102100035793 CD83 antigen Human genes 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 2
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims description 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 2
- 101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 claims description 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 2
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims description 2
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 2
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims description 2
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 2
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims description 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 2
- 102100027009 Toll-like receptor 10 Human genes 0.000 claims description 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 2
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims description 2
- 102100039387 Toll-like receptor 6 Human genes 0.000 claims description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims description 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 36
- 108090000623 proteins and genes Proteins 0.000 description 19
- 210000004408 hybridoma Anatomy 0.000 description 17
- 210000004881 tumor cell Anatomy 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 108010044292 tryptophyltyrosine Proteins 0.000 description 10
- 241000880493 Leptailurus serval Species 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 6
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 6
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 6
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 6
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 6
- ZFBBMCKQSNJZSN-AUTRQRHGSA-N Gln-Val-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZFBBMCKQSNJZSN-AUTRQRHGSA-N 0.000 description 6
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 6
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 6
- DBUNZBWUWCIELX-JHEQGTHGSA-N Gly-Thr-Glu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O DBUNZBWUWCIELX-JHEQGTHGSA-N 0.000 description 6
- KSOBNUBCYHGUKH-UWVGGRQHSA-N Gly-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN KSOBNUBCYHGUKH-UWVGGRQHSA-N 0.000 description 6
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 6
- HXWALXSAVBLTPK-NUTKFTJISA-N Leu-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(C)C)N HXWALXSAVBLTPK-NUTKFTJISA-N 0.000 description 6
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 6
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 6
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 6
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 6
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 6
- IXHKPDJKKCUKHS-GARJFASQSA-N Lys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IXHKPDJKKCUKHS-GARJFASQSA-N 0.000 description 6
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 6
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 6
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 6
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 6
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 6
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 6
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 6
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 6
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 6
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 6
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 6
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 6
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 6
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 6
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 6
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 6
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 6
- 108010087924 alanylproline Proteins 0.000 description 6
- 108010008355 arginyl-glutamine Proteins 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 6
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 6
- 108010015792 glycyllysine Proteins 0.000 description 6
- 108010037850 glycylvaline Proteins 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 108010003137 tyrosyltyrosine Proteins 0.000 description 6
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 5
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 description 5
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 5
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 5
- UISQLSIBJKEJSS-GUBZILKMSA-N Arg-Arg-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(O)=O UISQLSIBJKEJSS-GUBZILKMSA-N 0.000 description 5
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 5
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 5
- UGXYFDQFLVCDFC-CIUDSAMLSA-N Asn-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O UGXYFDQFLVCDFC-CIUDSAMLSA-N 0.000 description 5
- JBDLMLZNDRLDIX-HJGDQZAQSA-N Asn-Thr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O JBDLMLZNDRLDIX-HJGDQZAQSA-N 0.000 description 5
- SVFOIXMRMLROHO-SRVKXCTJSA-N Asp-Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SVFOIXMRMLROHO-SRVKXCTJSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 5
- STHSGOZLFLFGSS-SUSMZKCASA-N Gln-Thr-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O STHSGOZLFLFGSS-SUSMZKCASA-N 0.000 description 5
- WPJDPEOQUIXXOY-AVGNSLFASA-N Gln-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O WPJDPEOQUIXXOY-AVGNSLFASA-N 0.000 description 5
- RFTVTKBHDXCEEX-WDSKDSINSA-N Glu-Ser-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RFTVTKBHDXCEEX-WDSKDSINSA-N 0.000 description 5
- RVGMVLVBDRQVKB-UWVGGRQHSA-N Gly-Met-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN RVGMVLVBDRQVKB-UWVGGRQHSA-N 0.000 description 5
- XHVONGZZVUUORG-WEDXCCLWSA-N Gly-Thr-Lys Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN XHVONGZZVUUORG-WEDXCCLWSA-N 0.000 description 5
- BXDLTKLPPKBVEL-FJXKBIBVSA-N Gly-Thr-Met Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O BXDLTKLPPKBVEL-FJXKBIBVSA-N 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- KWHFUMYCSPJCFQ-NGTWOADLSA-N Ile-Thr-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N KWHFUMYCSPJCFQ-NGTWOADLSA-N 0.000 description 5
- HPBCTWSUJOGJSH-MNXVOIDGSA-N Leu-Glu-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HPBCTWSUJOGJSH-MNXVOIDGSA-N 0.000 description 5
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 5
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 5
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 5
- YYKZDTVQHTUKDW-RYUDHWBXSA-N Phe-Gly-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N YYKZDTVQHTUKDW-RYUDHWBXSA-N 0.000 description 5
- WEDZFLRYSIDIRX-IHRRRGAJSA-N Phe-Ser-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 WEDZFLRYSIDIRX-IHRRRGAJSA-N 0.000 description 5
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 5
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 5
- JAGGEZACYAAMIL-CQDKDKBSSA-N Tyr-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=C(C=C1)O)N JAGGEZACYAAMIL-CQDKDKBSSA-N 0.000 description 5
- BIWVVOHTKDLRMP-ULQDDVLXSA-N Tyr-Pro-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O BIWVVOHTKDLRMP-ULQDDVLXSA-N 0.000 description 5
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 5
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 5
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 5
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 5
- 108010044940 alanylglutamine Proteins 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 4
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 4
- PZZJMBYSYAKYPK-UWJYBYFXSA-N Ser-Ala-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O PZZJMBYSYAKYPK-UWJYBYFXSA-N 0.000 description 4
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 101000797612 Arabidopsis thaliana Protein MEI2-like 3 Proteins 0.000 description 3
- UZNSWMFLKVKJLI-VHWLVUOQSA-N Asp-Ile-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O UZNSWMFLKVKJLI-VHWLVUOQSA-N 0.000 description 3
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 3
- 101000603882 Homo sapiens Nuclear receptor subfamily 1 group I member 3 Proteins 0.000 description 3
- 101000857682 Homo sapiens Runt-related transcription factor 2 Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- IUVYJBMTHARMIP-PCBIJLKTSA-N Phe-Asp-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O IUVYJBMTHARMIP-PCBIJLKTSA-N 0.000 description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102100025368 Runt-related transcription factor 2 Human genes 0.000 description 3
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 3
- JWHOIHCOHMZSAR-QWRGUYRKSA-N Tyr-Asp-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JWHOIHCOHMZSAR-QWRGUYRKSA-N 0.000 description 3
- UUJHRSTVQCFDPA-UFYCRDLUSA-N Tyr-Tyr-Val Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 UUJHRSTVQCFDPA-UFYCRDLUSA-N 0.000 description 3
- MYLNLEIZWHVENT-VKOGCVSHSA-N Val-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](C(C)C)N MYLNLEIZWHVENT-VKOGCVSHSA-N 0.000 description 3
- 108010047857 aspartylglycine Proteins 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 208000010749 gastric carcinoma Diseases 0.000 description 3
- 239000006481 glucose medium Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 201000000498 stomach carcinoma Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 108010038745 tryptophylglycine Proteins 0.000 description 3
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 2
- LYILPUNCKACNGF-NAKRPEOUSA-N Ala-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N LYILPUNCKACNGF-NAKRPEOUSA-N 0.000 description 2
- 239000012114 Alexa Fluor 647 Substances 0.000 description 2
- DTNUIAJCPRMNBT-WHFBIAKZSA-N Asp-Gly-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O DTNUIAJCPRMNBT-WHFBIAKZSA-N 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 101150040844 Bin1 gene Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 108010011559 alanylphenylalanine Proteins 0.000 description 2
- 238000011091 antibody purification Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000012561 harvest cell culture fluid Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- GYNQVPIDAQTZOY-ROUUACIJSA-N (2s)-2-[[2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoic acid Chemical compound C([C@H](N)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 GYNQVPIDAQTZOY-ROUUACIJSA-N 0.000 description 1
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- SVBXIUDNTRTKHE-CIUDSAMLSA-N Ala-Arg-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O SVBXIUDNTRTKHE-CIUDSAMLSA-N 0.000 description 1
- MKZCBYZBCINNJN-DLOVCJGASA-N Ala-Asp-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MKZCBYZBCINNJN-DLOVCJGASA-N 0.000 description 1
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 1
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 1
- HQIZDMIGUJOSNI-IUCAKERBSA-N Arg-Gly-Arg Chemical compound N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQIZDMIGUJOSNI-IUCAKERBSA-N 0.000 description 1
- COXMUHNBYCVVRG-DCAQKATOSA-N Arg-Leu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O COXMUHNBYCVVRG-DCAQKATOSA-N 0.000 description 1
- UIUXXFIKWQVMEX-UFYCRDLUSA-N Arg-Phe-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O UIUXXFIKWQVMEX-UFYCRDLUSA-N 0.000 description 1
- ULBHWNVWSCJLCO-NHCYSSNCSA-N Arg-Val-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N ULBHWNVWSCJLCO-NHCYSSNCSA-N 0.000 description 1
- CTQIOCMSIJATNX-WHFBIAKZSA-N Asn-Gly-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O CTQIOCMSIJATNX-WHFBIAKZSA-N 0.000 description 1
- GZXOUBTUAUAVHD-ACZMJKKPSA-N Asn-Ser-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GZXOUBTUAUAVHD-ACZMJKKPSA-N 0.000 description 1
- LRCIOEVFVGXZKB-BZSNNMDCSA-N Asn-Tyr-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LRCIOEVFVGXZKB-BZSNNMDCSA-N 0.000 description 1
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 1
- JSNWZMFSLIWAHS-HJGDQZAQSA-N Asp-Thr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O JSNWZMFSLIWAHS-HJGDQZAQSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000037914 B-cell disorder Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001522296 Erithacus rubecula Species 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- HHWQMFIGMMOVFK-WDSKDSINSA-N Gln-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O HHWQMFIGMMOVFK-WDSKDSINSA-N 0.000 description 1
- XKBASPWPBXNVLQ-WDSKDSINSA-N Gln-Gly-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O XKBASPWPBXNVLQ-WDSKDSINSA-N 0.000 description 1
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 1
- OSCLNNWLKKIQJM-WDSKDSINSA-N Gln-Ser-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O OSCLNNWLKKIQJM-WDSKDSINSA-N 0.000 description 1
- CSMHMEATMDCQNY-DZKIICNBSA-N Gln-Val-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CSMHMEATMDCQNY-DZKIICNBSA-N 0.000 description 1
- MXOODARRORARSU-ACZMJKKPSA-N Glu-Ala-Ser Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)N MXOODARRORARSU-ACZMJKKPSA-N 0.000 description 1
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 1
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- KAJAOGBVWCYGHZ-JTQLQIEISA-N Gly-Gly-Phe Chemical compound [NH3+]CC(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 KAJAOGBVWCYGHZ-JTQLQIEISA-N 0.000 description 1
- DENRBIYENOKSEX-PEXQALLHSA-N Gly-Ile-His Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 DENRBIYENOKSEX-PEXQALLHSA-N 0.000 description 1
- IALQAMYQJBZNSK-WHFBIAKZSA-N Gly-Ser-Asn Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O IALQAMYQJBZNSK-WHFBIAKZSA-N 0.000 description 1
- CSMYMGFCEJWALV-WDSKDSINSA-N Gly-Ser-Gln Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O CSMYMGFCEJWALV-WDSKDSINSA-N 0.000 description 1
- VNNRLUNBJSWZPF-ZKWXMUAHSA-N Gly-Ser-Ile Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNNRLUNBJSWZPF-ZKWXMUAHSA-N 0.000 description 1
- ZVXMEWXHFBYJPI-LSJOCFKGSA-N Gly-Val-Ile Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZVXMEWXHFBYJPI-LSJOCFKGSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- NULSANWBUWLTKN-NAKRPEOUSA-N Ile-Arg-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N NULSANWBUWLTKN-NAKRPEOUSA-N 0.000 description 1
- JODPUDMBQBIWCK-GHCJXIJMSA-N Ile-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O JODPUDMBQBIWCK-GHCJXIJMSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- YIBOAHAOAWACDK-QEJZJMRPSA-N Lys-Ala-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YIBOAHAOAWACDK-QEJZJMRPSA-N 0.000 description 1
- PXHCFKXNSBJSTQ-KKUMJFAQSA-N Lys-Asn-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N)O PXHCFKXNSBJSTQ-KKUMJFAQSA-N 0.000 description 1
- SKRGVGLIRUGANF-AVGNSLFASA-N Lys-Leu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SKRGVGLIRUGANF-AVGNSLFASA-N 0.000 description 1
- FPQMQEOVSKMVMA-ACRUOGEOSA-N Lys-Tyr-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)NC(=O)[C@H](CCCCN)N)O FPQMQEOVSKMVMA-ACRUOGEOSA-N 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- YCCUXNNKXDGMAM-KKUMJFAQSA-N Phe-Leu-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YCCUXNNKXDGMAM-KKUMJFAQSA-N 0.000 description 1
- YMIZSYUAZJSOFL-SRVKXCTJSA-N Phe-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O YMIZSYUAZJSOFL-SRVKXCTJSA-N 0.000 description 1
- BAONJAHBAUDJKA-BZSNNMDCSA-N Phe-Tyr-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CC=CC=C1 BAONJAHBAUDJKA-BZSNNMDCSA-N 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- FMLRRBDLBJLJIK-DCAQKATOSA-N Pro-Leu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FMLRRBDLBJLJIK-DCAQKATOSA-N 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- MMGJPDWSIOAGTH-ACZMJKKPSA-N Ser-Ala-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MMGJPDWSIOAGTH-ACZMJKKPSA-N 0.000 description 1
- BCKYYTVFBXHPOG-ACZMJKKPSA-N Ser-Asn-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N BCKYYTVFBXHPOG-ACZMJKKPSA-N 0.000 description 1
- XWCYBVBLJRWOFR-WDSKDSINSA-N Ser-Gln-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O XWCYBVBLJRWOFR-WDSKDSINSA-N 0.000 description 1
- RWDVVSKYZBNDCO-MELADBBJSA-N Ser-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CO)N)C(=O)O RWDVVSKYZBNDCO-MELADBBJSA-N 0.000 description 1
- ADJDNJCSPNFFPI-FXQIFTODSA-N Ser-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO ADJDNJCSPNFFPI-FXQIFTODSA-N 0.000 description 1
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
- ODRUTDLAONAVDV-IHRRRGAJSA-N Ser-Val-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ODRUTDLAONAVDV-IHRRRGAJSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- LVHHEVGYAZGXDE-KDXUFGMBSA-N Thr-Ala-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)O)N)O LVHHEVGYAZGXDE-KDXUFGMBSA-N 0.000 description 1
- GUHLYMZJVXUIPO-RCWTZXSCSA-N Thr-Met-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O GUHLYMZJVXUIPO-RCWTZXSCSA-N 0.000 description 1
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 1
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 1
- KZTLZZQTJMCGIP-ZJDVBMNYSA-N Thr-Val-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KZTLZZQTJMCGIP-ZJDVBMNYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- KWAIRYFEWMLWPQ-UHFFFAOYSA-N Trp Gly Ser Tyr Chemical compound C=1NC2=CC=CC=C2C=1CC(N)C(=O)NCC(=O)NC(CO)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 KWAIRYFEWMLWPQ-UHFFFAOYSA-N 0.000 description 1
- OTWIOROMZLNAQC-XIRDDKMYSA-N Trp-His-Asp Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(O)=O OTWIOROMZLNAQC-XIRDDKMYSA-N 0.000 description 1
- NOXKHHXSHQFSGJ-FQPOAREZSA-N Tyr-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NOXKHHXSHQFSGJ-FQPOAREZSA-N 0.000 description 1
- OJCISMMNNUNNJA-BZSNNMDCSA-N Tyr-Tyr-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CC=C(O)C=C1 OJCISMMNNUNNJA-BZSNNMDCSA-N 0.000 description 1
- WYOBRXPIZVKNMF-IRXDYDNUSA-N Tyr-Tyr-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(O)=O)C1=CC=C(O)C=C1 WYOBRXPIZVKNMF-IRXDYDNUSA-N 0.000 description 1
- YODDULVCGFQRFZ-ZKWXMUAHSA-N Val-Asp-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O YODDULVCGFQRFZ-ZKWXMUAHSA-N 0.000 description 1
- MJOUSKQHAIARKI-JYJNAYRXSA-N Val-Phe-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 MJOUSKQHAIARKI-JYJNAYRXSA-N 0.000 description 1
- DOFAQXCYFQKSHT-SRVKXCTJSA-N Val-Pro-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DOFAQXCYFQKSHT-SRVKXCTJSA-N 0.000 description 1
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000010359 gene isolation Methods 0.000 description 1
- 108010075431 glycyl-alanyl-phenylalanine Proteins 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010084389 glycyltryptophan Proteins 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及一种嵌合抗原受体，编码其的核酸和表达其的细胞，以及其在制备治疗肿瘤的药物中的用途。本发明嵌合抗原受体，其包含至少一个胞外结构域、任选的跨膜结构域和至少一个胞内共刺激信号传导结构域，其中，所述胞外结构域包含CD19抗原识别结合结构域。本发明嵌合抗原受体经过人源化改造，体内存活期更长，患者完全缓解期也可相应延长。
Description
技术领域
本发明涉及肿瘤的细胞免疫治疗技术领域，具体地，涉及一种嵌合抗原受体，编码其的核酸和表达其的细胞，以及其在制备治疗肿瘤的药物中的用途。
背景技术
嵌合抗原受体(CAR,Chimeric Antigen Receptors)T细胞是表面表达识别特定抗原并能传递信号的嵌合型受体的T细胞。CAR T细胞通过表达嵌合抗原受体(CAR)分子而在抗肿瘤中发挥重要作用，CAR分子通常包括胞外段、跨膜区和胞内段：胞外段是由抗体重链和轻链可变区通过一条肽段相连接而形成的单链可变区(ScFv)；胞内段是各种信号传导分子的胞内段嵌合体，包括CD3zeta、CD28、OX-40、4-1BB等；跨膜区则来自其他分子(如CD8，CD4，CD28和CD3zeta)的跨膜区。单链可变片段部分的基因分离自例如产生识别靶抗原的单克隆抗体的杂交瘤。表达CAR分子的T细胞独立于肿瘤细胞上的主要组织相容性抗原I型的表达而直接识别肿瘤细胞表面抗原，并且在同时激活T细胞，并因此表达CAR的T细胞可以有效杀伤肿瘤细胞。简言之，CAR T细胞通过抗原-抗体识别模式对肿瘤细胞表面的特异分子进行识别，然后通过其胞内的信号传导进行激活、增殖并发挥细胞杀伤功能。
人源化CD19抗体在治疗B细胞疾病如淋巴瘤、白血病或自身免疫病中的应用(参见Hansen，美国专利申请公开号US2005/0070693)。尽管近年来癌症治疗取得很多进展，但B细胞恶性肿瘤，如非霍奇金淋巴瘤的B细胞亚型和慢性淋巴细胞性白血病仍然是主要的癌症相关死亡原因。因此，非常需要进一步改进的治疗方案来治疗B细胞恶性肿瘤。
CAR-T的中文全称为嵌合抗原受体T细胞免疫疗法，是目前炙手可热的新型肿瘤治疗方式，也被认为是最可能攻克恶性肿瘤的技术之一。但CAR-T治疗的广泛应用也正遭遇着一系列难题和瓶颈，其中宿主免疫系统包括T细胞和抗体介导的对CAR分子的免疫排斥反应可能是限制CAR-T细胞体内持续性和长期疗效的关键阻碍和影响其应用的重要因素之一。
发明内容
目前全球大多数临床注册的CD19CAR-T细胞治疗，所使用的肿瘤识别序列来源于鼠源抗体，回输人体后易被自身免疫系统识别为异种抗原，从而被宿主T细胞或抗体清除，继而影响CAR-T细胞体内的持续性，导致高复发率，并降低了长期临床疗效，对此，本发明的目的在于提供一种嵌合抗原受体及其应用，具体包括嵌合抗原受体以及编码其的核酸，表达其的细胞，其在制备治疗肿瘤的药物中的应用。本发明的嵌合抗原受体CD19抗体识别序列经过人源化改造，体内存活期更长，患者完全缓解期也可相应延长。
本发明通过以下技术方案实现上述目的：
第一方面，本发明提供了一种嵌合抗原受体，其包含至少一个胞外结构域、任选的跨膜结构域和至少一个胞内共刺激信号传导结构域，其中，所述胞外结构域包含CD19抗原识别结合结构域；
其中，所述CD19抗原识别结合结构域包含具有如SEQ ID NO.1-6之一所示的序列的重链可变区或与其具有至少85％序列同一性的变体；
所述CD19抗原识别结合结构域包含具有如SEQ ID NO.7-12之一所示的序列的轻链可变区或与其具有至少85％序列同一性的变体。
本发明中，将人源化的CD19特异性单链抗体序列构建人源化CD19 CAR T细胞可获得与鼠源CD19 CAR T细胞同样的治疗效应，但却避免了鼠单链抗体的免疫排斥反应；本申请中的CD19抗原识别结合结构域经过人源化改造，不影响其对肿瘤细胞靶点抗原的识别能力，同时可能降低异种免疫排斥的发生概率，从而提升CAR-T细胞在人体中的持续时间，增强其对肿瘤细胞的免疫监控能力，降低肿瘤复发率，患者完全缓解期也可相应延长。
在本发明的一些实施例中，所述CD19抗原识别结合结构域的重链可变区的氨基酸序列与SEQ ID NO.1-6之一所示的氨基酸序列具有至少85％，例如可以是85％、86％、88％、90％、92％、95％、98％、99％同一性的序列，且具有结合CD19和诱导T细胞信号传导的能力的变体，优选为具有至少90％，优选95％序列同一性的变体的重链可变区，且具有结合CD19和诱导T细胞信号传导的能力的变体。
在本发明的一些实施例中，所述CD19抗原识别结合结构域的重链可变区的氨基酸序列与SEQ ID NO.7-12之一所示的氨基酸序列具有至少85％，例如可以是85％、86％、88％、90％、92％、95％、98％、99％同一性的序列，且具有结合CD19和诱导T细胞信号传导的能力的变体，优选为具有至少90％，优选95％序列同一性的变体的轻链可变区，且具有结合CD19和诱导T细胞信号传导的能力的变体。
根据本发明，所述CD19抗原识别结合结构域包含具有如SEQ ID NO.1-6之一所示的序列的重链可变区或与其具有至少85％，优选90％，进一步优选95％序列同一性，且具有结合CD19和诱导T细胞信号传导的能力的变体。
根据本发明，所述CD19抗原识别结合结构域包含具有如SEQ ID NO.7-12之一所示的序列的轻链可变区或与其具有至少85％，优选90％，进一步优选95％序列同一性，且具有结合CD19和诱导T细胞信号传导的能力的变体。
本发明中，发明人发现采用这6个序列的重链和轻链的组合能够进一步提高与杂交瘤抗体的亲和力，其杀伤效果也显著提升，具体的CD19抗原识别结合结构域的重链可变区和轻链可变区可以由重链和轻链其中一条进行组合，具体如下表1所示：
表1
根据本发明，所述嵌合抗原受体例如可以是重链为SEQ ID NO.1和轻链为SEQ IDNO.7组成，重链为SEQ ID NO.1和轻链为SEQ ID NO.8组成，重链为SEQ ID NO.1和轻链为SEQ ID NO.9组成，重链为SEQ ID NO.1和轻链为SEQ ID NO.10组成，重链为SEQ ID NO.1和轻链为SEQ ID NO.11组成，重链为SEQ ID NO.1和轻链为SEQ ID NO.12组成，重链为SEQ IDNO.2和轻链为SEQ ID NO.7组成，重链为SEQ ID NO.2和轻链为SEQ ID NO.8组成，重链为SEQ ID NO.2和轻链为SEQ ID NO.9组成，重链为SEQ ID NO.2和轻链为SEQ ID NO.10组成，重链为SEQ ID NO.2和轻链为SEQ ID NO.11组成，重链为SEQ ID NO.2和轻链为SEQ IDNO.12组成，重链为SEQ ID NO.3和轻链为SEQ ID NO.7组成，重链为SEQ ID NO.3和轻链为SEQ ID NO.8组成，重链为SEQ ID NO.3和轻链为SEQ ID NO.9组成，重链为SEQ ID NO.3和轻链为SEQ ID NO.10组成，重链为SEQ ID NO.3和轻链为SEQ ID NO.11组成，重链为SEQ IDNO.3和轻链为SEQ ID NO.12组成，重链为SEQ ID NO.4和轻链为SEQ ID NO.7组成，重链为SEQ ID NO.4和轻链为SEQ ID NO.8组成，重链为SEQ ID NO.4和轻链为SEQ ID NO.9组成，重链为SEQ ID NO.4和轻链为SEQ ID NO.10组成，重链为SEQ ID NO.4和轻链为SEQ IDNO.11组成，重链为SEQ ID NO.4和轻链为SEQ ID NO.12组成，重链为SEQ ID NO.5和轻链为SEQ ID NO.7组成，重链为SEQ ID NO.5和轻链为SEQ ID NO.8组成，重链为SEQ ID NO.5和轻链为SEQ ID NO.9组成，重链为SEQ ID NO.5和轻链为SEQ ID NO.10组成，重链为SEQ IDNO.5和轻链为SEQ ID NO.11组成，重链为SEQ ID NO.5和轻链为SEQ ID NO.12组成，重链为SEQ ID NO.6和轻链为SEQ ID NO.7组成，重链为SEQ ID NO.6和轻链为SEQ ID NO.8组成，重链为SEQ ID NO.6和轻链为SEQ ID NO.9组成，重链为SEQ ID NO.6和轻链为SEQ IDNO.10组成，重链为SEQ ID NO.6和轻链为SEQ ID NO.11组成，或重链为SEQ ID NO.6和轻链为SEQ ID NO.12组成。
在本发明的一些实施例中，所述CD19抗原识别结合结构域的重链可变区的氨基酸序列与SEQ ID NO.1-6之一所示的氨基酸序列具有至少85％，例如可以是85％、86％、88％、90％、92％、95％、98％、99％同一性的序列，且具有结合CD19和诱导T细胞信号传导的能力的变体，优选为具有至少90％，优选95％序列同一性的变体的重链可变区，且具有结合CD19和诱导T细胞信号传导的能力的变体。
在本发明的一些实施例中，所述CD19抗原识别结合结构域的重链可变区的氨基酸序列与SEQ ID NO.7-12之一所示的氨基酸序列具有至少85％，例如可以是85％、86％、88％、90％、92％、95％、98％、99％同一性的序列，且具有结合CD19和诱导T细胞信号传导的能力的变体，优选为具有至少90％，优选95％序列同一性的变体的轻链可变区，且具有结合CD19和诱导T细胞信号传导的能力的变体。
根据本发明，所述嵌合抗原受体的胞外结构域还包括任选的信号肽结构域，所述信号肽结构域为GM-CSF信号肽、IL-2信号肽或CD8α信号肽中的任意一种。
根据本发明，所述胞内结构域还包括胞内共刺激信号传导域和/或CD3ζ信号传导域，所述胞内共刺激信号传导域包括人CD28胞内区、人4-1BB胞内区、人TLR1胞内区、人TLR2胞内区、人TLR3胞内区、人TLR4胞内区、人TLR5胞内区、人TLR6胞内区、人TLR7胞内区、人TLR8胞内区、人TLR9胞内区、人TLR10胞内区、人DAP10胞内区、人CD27胞内区、人OX40胞内区、人CD30胞内区、人CD40胞内区、人PD-1胞内区、人CTLA-4胞内区、人TIM3胞内区、人LAG3胞内区、人TGFβ胞内区、人ICOS胞内区、人淋巴细胞功能相关抗原1胞内区、人CD2胞内区、人CD7胞内区、人LIGHT胞内区、人NKG2C胞内区、人NKG2D胞内区、人NKp46胞内区、人NKp30胞内区、人NKp44胞内区、人DNAM1胞内区、人B7-H3胞内区或人CD83胞内区中的任意一种或至少两种的组合，优选为人CD28胞内区、人4-1BB胞内区、人TLR2胞内区或人DAP10胞内区×3、人DAP10胞内区×6、人DAP10胞内区×9中的任意一种或至少两种的组合(所述组合例如可以是CD28-TLR2、41BB-TLR2、41BB-CD28、41BB-CD28-TLR2、41BB-CD28-DAP10×3、41BB-TLR2-DAP10×3、CD28-TLR2-DAP10×3、TLR2-DAP10×3、CD28-DAP10×3、41BB-DAP10×3、TLR2-DAP10×6、CD28-DAP10×6、41BB-DAP10×9、TLR2-DAP10×9、CD28-DAP10×9或41BB-DAP10×9)优选为人CD28胞内区、人4-1BB胞内区、人TLR2胞内区和人DAP10×3胞内区任意一种或至少两种的组合。
所述跨膜结构域还包括任选的信号肽结构域，优选为CD3、CD8、CD28、OX40或ICOS中的任意一种，进一步优选为CD28。
第二方面，本发明提供编码如第一方面所述的嵌合抗原受体的核酸。
第三方面，本发明提供一种嵌合抗原受体表达细胞，其中引入了如第一方面所述的核酸。
根据本发明，所述细胞为T细胞或含有T细胞的细胞群。
第四方面，本发明提供制备如第三方面所述的嵌合抗原受体表达细胞的方法，其包括将如第二方面所述的核酸引入细胞的步骤。
优选地，所述细胞为T细胞或含有T细胞的细胞群。
第五方面，本发明提供如第一方面所述的嵌合抗原受体、如第二方面所述的核酸或如第三方面所述的嵌合抗原受体表达细胞在制备治疗肿瘤的药物中的用途。
优选地，所述肿瘤为CD19阳性恶性肿瘤和/或B细胞恶性肿瘤。
第六方面，本发明提供一种治疗肿瘤的药物组合，包括如第一方面所述的嵌合抗原受体、如第二方面所述的核酸或如第三方面所述的嵌合抗原受体表达细胞中的任意一种或至少两种的组合；
优选地，所述药物组合还包括免疫治疗药物和/或小分子药物。
本发明中，所述免疫治疗药物，例如可以是抗BCMA嵌合抗原受体、抗CD20嵌合抗原受体、抗CD22嵌合抗原受体、抗CD20单克隆抗体、BCR-ABL激酶抑制剂、免疫检查点抑制剂(PD-1/PD-L1单克隆抗体、CTLA-4单克隆、TIM3单克隆抗体、LAG3单克隆抗体)、PD-1/PD-L1嵌合抗原受体、CTLA-4嵌合抗原受体、TIM3嵌合抗原受体或LAG3嵌合抗原受体中的任意一种或至少两种的组合。
本发明中，所述药物组合还包括小分子化学药物，例如可以是长春新碱、柔红霉素、左旋门冬酰胺酶、强的松、吡柔比星、地塞米松、天冬酰胺酶、阿霉素、阿糖胞苷或培门冬酶、MTOR抑制剂(替西罗莫司，依维莫司，西罗莫司)、蛋白酶体抑制剂(硼替佐米、卡非佐米、伊沙佐米)或组蛋白去乙酰化酶(HDAC)抑制剂(贝利司他、伏立诺他、帕比司他)中的任意一种或至少两种的组合。
值得注意的是，术语“胞内结构域”是指已知在细胞中作为传输信号以引起生物过程的活化或抑制的结构域起作用的任何寡肽或多肽。
值得注意的是，术语“变体”是指包含一个或几个至多个氨基酸的取代、缺失或添加的任何变体，条件是所述变体基本上保留原始序列所具有的相同功能。
与现有技术相比，本申请具有如下有益效果：
本申请中的CD19抗原识别结合结构域经过人源化改造，不影响其对肿瘤细胞靶点抗原的识别能力，同时可能降低异种免疫排斥的发生概率，从而提升CAR-T细胞在人体中的持续时间，增强其对肿瘤细胞的免疫监控能力，降低肿瘤复发率，患者完全缓解期也可相应延长。
附图说明
图1为杂交瘤抗体与CD19-his结合的结果图，其中，图1A为15F2、55G1、27F11、38C1和22H1与杂交瘤抗体结合的结果，图1B为31A2、60G10、11H8、14G9和31F5与杂交瘤抗体结合的结果，图1C为68A3、56F4、17B6、28C10、52F9和80G7与杂交瘤抗体结合的结果，图1D为11H8、15F2、17B6、27F11、31A2和52F9和杂交瘤抗体结合的结果；
图2为CD19抗体表位结合结果图；
图3为亲和度最优的CD19抗体的结合分析；
图4为CD19抗体与不同抗原亲和度分析，其中，图4A为16B7、21F1、32G7、21G5、22A3、12D1、15F2、55G1、27F11、51E9、38C1、22H1、31A2、27B9和44C12抗原与CD19抗体结合的结果，图4B为60G10、11H8、14G9、31F5、16D4、31G6、32G11、55D9、16G6、80G5、68A3、56F4、17B6、28C10、52F9和80G7抗原与CD19抗体结合的结果；
图5为CD19完全人源化抗体与CD19-his结合结果图；
图6为CD19完全人源化抗体与Nalm6/GL结合结果图；
图7为嵌合抗原受体CAR 19SCFV分子结构图；
图8为CAR(11H8/31A2/52F9/FMC63)-41BB-TLR2-CD3ζT细胞体外靶向杀伤CD19+淋巴瘤细胞系RAJI；
图9为CAR(15F2/17B6/27F11/31A2/FMC63)-41BB-TLR2-CD3ζT细胞体外靶向杀伤CD19+淋巴瘤细胞系RAJI；
图10为CAR(11H8/31A2/52F9/FMC63)-CD28-TLR2-CD3ζT细胞体外靶向杀伤CD19+白血病细胞系NALM6；
图11为CAR(15F2/17B6/27F11/31A2/FMC63)-41BB-DAP10×3-CD3ζT细胞体外靶向杀伤CD19+白血病细胞系NALM6；
图12为CAR(11H8/31A2/52F9/FMC63)-41BB-TLR2-CD3ζT细胞对CD19-急性髓系白血病细胞系AML3体外杀伤结果；
图13为CAR(15F2/17B6/27F11/31A2/FMC63)-41BB-CD28-CD3ζT细胞对CD19-急性髓系白血病细胞系AML3体外杀伤结果；
图14为CAR(11H8/31A2/52F9/FMC63)-41BB-TLR2-CD3ζT细胞对肺癌细胞系A549体外杀伤结果；
图15为CAR(11H8/31A2/52F9/FMC63)-CD28-TLR2-CD3ζT细胞对肺癌细胞系H460体外杀伤结果；
图16为CAR(11H8/31A2/52F9/FMC63)-41BB-TLR2-CD3ζT细胞对胃癌细胞系MKN28体外杀伤结果；
图17为CAR(11H8/31A2/52F9/FMC63)-CD28-TLR2-CD3ζT细胞对胃癌细胞系SNU-1体外杀伤结果；
图18为CAR(15F2/17B6/27F11/31A2/FMC63)-41BB-DAP10×3-CD3ζT细胞对胃癌细胞系SNU-1体外杀伤结果；
图19为CAR(11H8/31A2/52F9/FMC63)-41BB-DAP10×3-CD3ζT细胞对肝癌细胞系SMMC体外杀伤结果；
图20为CAR(15F2/17B6/27F11/31A2/FMC63)-41BB-DAP10×3-CD3ζT细胞对肝癌细胞系HepG2体外杀伤结果。
具体实施方式
为便于理解本发明，本发明列举实施例如下。本领域技术人员应该明了，所述实施例仅仅是帮助理解本发明，不应视为对本发明的具体限制。
CAR质粒的构建
如上所述，CAR分子包括胞外区域、跨膜区域、胞内区域，因此，以下实施例所用CAR质粒的构建步骤包括：
首先，通过基因合成获得CAR质粒所需各基因DNA，包括：抗CD19抗体免疫球蛋白重链和轻链的可变区域序列、CD28跨膜信号区域序列、TLR1信号传递区域序列、TLR2信号传递区域序列、DAP10×3信号传递区域序列、CD3ζ信号传递区域序列；
然后，通过酶切、连接等步骤将所需要的上述合成的各基因序列串联起来，即获得本发明的CAR分子。
材料：
hCD19-fc购于ACRO Biosystems Cat#CD9-H5259
hCD19-his购于ACRO Biosystems Cat#CD9-H52H2；
具体实施例
实施例1hCD19蛋白的制备和鉴定
按如下步骤制备Hcd19蛋白，具体如下：
hCD19-fc：在HEK293细胞中表达人类CD19重组蛋白(Accession#AAH06338)。选择人CD19基因编码区Pro20-Lys291序列(C端使用Fc标记)进行转染。用SDS-PAGE凝胶鉴定纯化后蛋白。
hCD19-his：在HEK293细胞中表达人类CD19重组蛋白(Accession#P15391-1)。选择人CD19基因编码区Pro20-Lys291序列(C端使用His标记)进行转染。用SDS-PAGE凝胶鉴定纯化后蛋白。
实施例2抗体制备
(I)抗原共轭结合和免疫
(1)将hCD19-Fc重组蛋白与多种MabSpace免疫增强肽进行免疫共轭，通过SDS-PAGE凝胶检测完成共轭蛋白质控；
(2)将以上共轭hCD19-Fc蛋白中以1:1比例加入弗氏完全佐剂(Pierce,Cat#77140)进行乳化，然后分别通过皮下和腹腔注射入H2L2小鼠进行免疫。H2L2小鼠由HarbourBioMed生产，携带人类可变区域和大鼠恒定区域的基因，且不含有内源性小鼠抗体基因。使用CpG(胞嘧啶-磷硫酰-鸟嘌呤)和明矾进行了额外的免疫，以保存蛋白质的天然结构。第1次免疫后，以及免疫产生后(至少每2周一次)获取小鼠血清，采用ELISA法分析抗血清中抗hCD19滴度。
(II)融合
在融合前4天，每只小鼠腹腔注射未共轭hCD19-His蛋白的PBS溶液。在融合当日，无菌操作获取小鼠脾脏，并剪切、研磨、过滤成单细胞悬浮液。裂解红细胞，用DMEM(Gibco)冲洗脾脏细胞。将活的、对数期生长的骨髓瘤细胞(SP2/0)以1:4比例与小鼠脾脏细胞混合。在与PEG(聚乙二醇)融合前清洗2次。融合后细胞用DMEM培养基清洗后，用10％FBS+HFCS(氢氟烃)+OPI+1×HAT细胞生长培养基重悬。置于96孔细胞培养板，每孔200μl细胞生长培养基，于37℃、湿润、10％二氧化碳培养箱培养过夜。培养7天，每2-3天，吸出杂交瘤培养基上清(抗体筛选备用)，更换新鲜培养基。
(III)ELISA筛选抗体
96孔板中加入1μg/ml人CD19-His，每孔100μl，在4℃孵育过夜；清洗后，加入100μl杂交瘤培养液上清，与人CD19-His完全结合；加入HRP(辣根过氧化物酶)标记的山羊抗大鼠Fc抗体，检测结合的CD19抗体；TMB反应并H2SO4终止后，在Thermo Multiscan FC(450nM)读数。ELISA检测阳性的杂交瘤细胞继续培养，继续进一步鉴定分析。
实施例3阳性杂交瘤细胞亚克隆获取和小规模抗体生产
(I)阳性杂交瘤细胞亚克隆
(1)在96孔板上进行ELISA阳性杂交瘤细胞梯度稀释，选取具有理想亲和性和阻断活性的细胞；培养7天后，形成细胞克隆团，收集上清，通过抗原结合能力采用实施例2中的方式进一步筛选；
(2)通过筛选结果选取具有最高的抗原亲和性的克隆，在杂交瘤生长培养基中扩增培养。7天后，再次检测筛选后的杂交瘤细胞培养液上清的抗原结合能力；亚克隆筛选试验至少两次以上，直到至少90个孔(96孔板)；
(3)当90多个井显示阳性结合信号时，鉴定出两个抗原结合活性最高的克隆，并将其转移到24孔板培养基中，允许其继续生长2天；一旦24孔板汇合，细胞被转移到6孔板；孵育5天后，部分细胞被冷冻。剩余的细胞被转移到一个烧瓶中并允许扩张；一旦烧瓶汇合，一半的细胞被冷冻(每个克隆3瓶)以作额外的备份，另一半则被允许在培养基中进一步扩大以生产抗体，使用标准方法确定同型。
(II)单克隆抗体的小规模生产
(1)将杂交瘤细胞接种于滚瓶，用200-300ml杂交瘤培养基(Invitrogen公司)培养14天，从杂交细胞培养中纯化CD19单克隆抗体(mAbs)如下：所有净化过程均在室温下进行，采用亲和层析法纯化各种单克隆抗体；
(2)离心分离寄主细胞培养液(CCF，cell culture fluid)以清除细胞碎片，然后将CCF上清液过滤、稀释，然后以柱状、蛋白G高效(Bio-Rad)和平衡的形式加载到蛋白G层析培养基上；
(3)负载后，蛋白G柱被洗涤直到280nm处的吸光度回到基线，CD19单克隆抗体用pH值2.5甘氨酸洗脱，然后立刻加入1M Tris(每1mL洗脱液)中和，以洗脱液280nm的吸光度为对照，收集含蛋白组分，使蛋白成池；
(4)纯化后，通过10,000MWCO膜(皮尔斯滑液裂解器或透析管)透析的CD19单克隆抗体利用PBS配置制成，配置完成后，过滤CD19单克隆抗体。
实施例4ELISA法纯化CD19抗体的结合分析
按照实施例2，用ELISA法筛选抗体。简单地，0.5μg/ml hCD19-His(ACRO)孵育涂层，连续稀释纯化抗体将与孵育抗原结合，利用HRP标记的山羊抗大鼠Fc抗体可以检测到各抗体的结合信号。
用Graphpad Prism软件计算拟合数据，抗体EC50汇总见图1和表2所示：
表2
| 抗体 | EC50(ng/ml) | 抗体 | EC50(ng/ml) |
| 16B7 | 60.5 | 55D9 | 25.9 |
| 21F1 | 46.6 | 16G6 | 31.5 |
| 32G7 | 58.8 | 80G5 | 24.6 |
| 21G5 | 60.0 | 68A3 | 31.2 |
| 22A3 | 40.9 | 31F5 | 119.7 |
| 12D1 | 57.1 | 56F4 | 19.3 |
| 15F2 | 28.7 | 17B6 | 175.9 |
| 55G1 | 59.2 | 28C10 | 56.1 |
| 27F11 | 67.2 | 52F9 | 59.2 |
| 51E9 | 2108.0 | 80G7 | 25.8 |
| 38C1 | 20.8 | 30E7 | 5286.0 |
| 22H1 | 23.6 | 44C9 | 224.2 |
| 31A2 | 24.9 | 26C2 | 295.0 |
| 29C12 | ～215395 | 21D5 | 32177.0 |
| 27B9 | 46.8 | 46E6 | 2.494e+006 |
| 44C12 | 75.9 | 47D8 | 14877.0 |
| 60G10 | 608.8 | 45E9 | 446.1 |
| 11H8 | 30.1 | 40D3 | 72.1 |
| 14G9 | 33.9 | 24E10 | 129.0 |
| 31F5 | 29.2 | 19D6 | 73.7 |
| 16D4 | 33.0 | 15H10 | 30791.0 |
| 31G6 | 26.8 | 31F11 | 238.9 |
| 22G11 | 66.6 |
从图1和表2可以看出，抗体与hCD19-His的亲和力不同，但与hCD19-His都有一定的亲和力，选择这些抗体作为嵌合抗原受体的胞外结构域能够实现识别CD19的功能。
实施例5通过Fortiebio方法进行表位结合
第一个CD19抗体用动力学缓冲液(PBS)稀释在装载列微型板块(Greiner Bio-one)，250μl/孔，hCD19-his用动力学缓冲液(PBS)稀释在关联列(Association Column)，250μl/孔；将AHC传感器放置在第一个基线中，得到第一个基线，然后在装载列中放置300秒，以捕获第一个CD19抗体，然后将传感器放置在第二个基线列中，得到第二个基线；然后将它们放入关联列300秒，让CD19/1CD19抗体完全关联，将传感器放置在第二个CD19抗体列300秒，让第二个CD19抗体与第一Ab竞争/不竞争，用ForteBio(Octet96)分析数据，结果如图2和表3所示，具体如下：
表3
从图2示例性可以看出，如果第二个CD19Ab不能与CD19结合，说明它与第一个具有相似的表位并与之竞争；如果第二种抗体可以不受第一抗体的影响与第一种结合而不产生任何影响，那么它们的表位是不同的，是非竞争的。根据这个结果，根据竞争结果将抗体分为两组，两组表位不同，结果如表3所示，大部分属于Bin1，只有两个抗体属于Bin2。
实施例6用流式细胞仪(FACS)对纯化的CD19抗体进行结合分析
收集指数期增长CD19表达肿瘤细胞Nalm6在PBS和重悬细胞密度105/孔，100μl/孔，在孔中加入稀释CD19抗体，4℃孵育1小时；利用流式细胞仪清洗缓冲液清洗细胞三次，加入抗大鼠IgG-Alexa Fluor 647(Abcam,Cat#ab150163)4℃孵育1h；用流式细胞仪洗涤缓冲液清洗细胞3次，流式细胞仪分析样品，结果如图3和表4所示，具体如下：
表4
如表3所示，27F11、17B6、31A2、11H8、27B9和15F2对Nalm6的结合信号最高。背景(抗大鼠IgG-Alexa Fluor 647)的MFI(mean fluorescence intensity平均荧光强度)约为450；从图3可以看出，两箱(Bin)抗体的结合曲线不同：Bin1的27F11、17B6、31A2和11H8结合信号较高，EC50也较高；Bin2的55G1和52F9信号较低，EC50较低。
实施例7特异性结合(ELISA)
根据实施例4中所述方法，0.5μg/ml hCD19-His、hVISTA-his、hPD-L1、hCD40、h41BB和hLAG3分别涂层孵育，加入2μg/ml纯化抗体以绑定孵育抗原，利用HRP标记的山羊抗大鼠Fc抗体可以检测抗体结合信号，结果如图4所示。
如图4所示，这些抗体16B7、21F1、32G7、21G5、22A3、12D1、15F2、55G1、27F11、51E9、38C1、22H1、31A2、27B9、44C12、60G10、11H8、14G9、31F5、16D4、31G6、32G11、55D9、16G6、80G5、68A3、56F4、17B6、28C10、52F9和80G7均未与(除hCD19外)其他抗原发生交叉反应，表明抗体对CD19具有良好的特异性。
实施例8杂交抗体的基因克隆和测序
通过聚合酶链反应(PCR)扩增获得大鼠抗人CD19抗体轻链和重链可变区序列。利用RNA提取试剂盒(TAKARA)分别从表达11H8、17B6、31A2、27F11、15F2、19D6、52F9的杂交瘤细胞中提取总RNA，用PrimeScript II第一链cDNA合成试剂盒(TAKARA)合成cDNA(Oligo DT引物)。用简并正向引物和一个反向引物(由抗体同工型决定)克隆IgG基因的重链可变区，用mK-F正向引物和cK-R反向引物克隆轻链可变区。每个抗体产生的条带被克隆到反式-5a克隆载体中，10多个克隆的DNA使用DNA star测序仪器进行测定。
测序结果表明，15F2和19D6的氨基酸序列相同，因此，这个克隆命名为15F2，序列结果如表1所示，具体如下：
表1
实施例9完全人源化抗体的生产
测序分析和确认后，上述每一个基因的可变区克隆入重组表达载体，如轻链可变区序列(VL)融合人类免疫球蛋白IgG kappa恒定区克隆到pcDNA3.1(+)载体，重链可变区序列(VH)融合人类IgG1恒定区克隆到pcDNA3.1(+)载体，分别对抗体生产和纯化。
实施例10重组完全人源化抗体的表达和纯化
重组抗体蛋白的表达和纯化进行了以下步骤：
(1)密度(5-6)×106细胞/ml的ExpiCHO细胞用ExpiCHO表达培养基培养，随后，使用ExpiCHO转染试剂盒在ExpiCHO细胞转染入等量的重链载体和轻链载体，载体DNA最终浓度1.0μg/ml；转染细胞培养在摇动烧瓶125rpm，8％二氧化碳，37℃培养箱，转染后18-22小时添加ExpiCHO培养基；
(2)于第10天收集细胞混合培养物。通过离心获得富集细胞培养液(HCCF，HarvestCell Culture Fluid)，然后，将HCCF加到rProteinA柱(G.E.Healthcare)，用PBS清洗。用含有20mm柠檬酸的溶液(pH3.2)洗脱IgG抗体。最后，洗脱的抗体蛋白中和后，储存在-80℃长期使用，通过SDS-PAGE和尺寸排除色谱法(TSKgel G3000SWXL，TOSOH)分析产生的抗体以确定纯度。
实施例11纯化的人源化抗体的结合特性
(I)通过ELISA与人类CD19蛋白结合
根据实施例4所述方法，0.5μg/ml的hCD19-His涂层孵育，加入连续梯度稀释的完全人源化抗体与孵育抗原结合。利用HRP标记的山羊抗人Fc抗体可以检测到每个抗体的结合信号，结果如图5和表5所示，具体如下：
表5
| 11H8 | 15F2 | 17B6 | 27F11 | 31A2 | 52F9 | |
| EC50 | 2.629 | 3.779 | 4.522 | 3.995 | 4.458 | 7.916 |
从图5和表5可以看出，每个抗体的EC50约为2-8ng/ml，这说明抗体的结合亲和力非常高。
(Ⅱ)通过流式细胞技术FACS检测抗体与Nalm6细胞结合
根据实施例6所述方法，收集处于对数增长期的Nalm6细胞，离心用PBS重悬稀释，细胞密度105/100μl/孔，加入稀释的完全人源化抗体在4℃孵育1h。用流式细胞仪清洗缓冲液清洗细胞三次后，添加抗人IgG-Cy5(Abcam，Cat#ab97172)4℃孵育1h，用流式细胞仪洗涤缓冲液清洗细胞3次，流式细胞仪分析样品，结果如图6和表6所示，具体如下：
表6
| 11H8 | 15F2 | 17B6 | 27F11 | 31A2 | 52F9 | |
| EC50 | 2.056 | 4.161 | 5.026 | 2.809 | 4.763 | 1.567 |
从图6和表6可以看出，这些完全人源化抗体11H8、15F2、1786、27F11、31A2和52F9以剂量依赖性的方式与Nalm6细胞表达的CDl9结合，1786具有最高的结合信号。
实施例12利用完全人源化CD19抗体序列构建嵌合抗原受体T细胞
(I)嵌合抗原受体分子载体的构建
通过基因合成、分子克隆等手段获得分别嵌合抗CD19完全人源化单克隆抗体SCFV序列(如表1抗体序列)的pUC57-CAR 19SCFV(其中对照组为FMC63)，CAR分子结构如图7所示。
通过内切酶PmeI和SpeI对所得到的pUC57-CAR 19SCFV质粒进行酶切，获得CAR19SCFV基因，然后将CAR 19SCFV基因连接至慢病毒载体pWPXLd(含GFP基因)中，构建pWPXLd-CAR 19SCFV-GFP。
(II)嵌合抗原受体T细胞转染
可通过病毒载体转导法、基于转座子系统的电转法、以及脂质体介导的质粒转染等方式将嵌合抗原受体分子编码基因整合或转染免疫细胞，随后这些免疫系统在载体启动子驱动下表达该基因，从而使CAR分子受体表达于免疫细胞表面，此处采用慢病毒转导T细胞方法，具体如下：
(1)在150mm培养皿中培养处于对数增长期的293T细胞密度达80-90％时(培养基为：DMEM高糖培养基+10％FBS(胎牛血清)+1％双抗(100×青霉素-链霉素混合溶液))，更换培养基：DMEM高糖培养基+1％FBS+1％双抗；2-6小时后，用PEI将pWPXLd-CAR-GFP或对照质粒pWPXLd-GFP、pMD2.G和psPAX2三个质粒共同转化293T细胞；于转化后24、48和72小时，收集培养基上清，并加入新鲜培养基(DMEM高糖培养基+1％FBS+1％双抗)；培养基上清收集完毕，使用0.45uM PVDF滤膜过滤，去除细胞碎片，放置在4℃冰箱待用；
(2)T细胞的分离纯化：通过Ficoll密度梯度法分离出血液中的单个核细胞，经红细胞裂解液裂解去除红细胞后，再通过MACS Pan-T磁珠分选出T细胞；分选出来的T细胞用培养基AIM-V加5％FBS、青霉素100U/ml和链霉素0.1mg/ml稀释至浓度2.5×106个/ml待用；通过包被CD2、CD3、CD28抗体的磁珠(美天旎)刺激T细胞，根据美天旎提供的protocol进行刺激，即磁珠与T细胞比例为1:2，T细胞密度为5×106个/ml/cm2，T细胞在37℃、5％CO2培养箱培养刺激48h；
(3)T细胞的慢病毒转染：将激活后的T细胞中的磁珠通过磁场作用去除，300g离心5min，去上清，用新鲜培养基重悬，分别加入CAR载体慢病毒和8μg/ml的polybrene和300IU/ml IL-2，病毒加入量为MOI＝10。37℃，5％CO2培养箱培养24h后，300g离心5min，去上清，用含300IU/ml IL-2的新鲜培养基重悬，37℃、5％CO2培养箱培养；
(4)CAR T细胞扩增：将CAR T细胞密度维持在1×106个/ml左右，每2-3天进行一次半量换液。两周后，T细胞数可扩增100倍，GFP阳性的细胞为转染成功的CAR T细胞，GFP阳性比例通过流式进行检测，即得到CAR T细胞或对照T细胞的比例。
实施例13完全人源化抗体CAR T细胞对肿瘤细胞的体外特异性杀伤试验
(1)将实施例12制备的抗CD19完全人源化CAR T(不同SCFV序列15F2、17B6、27F11、31A2、11H8、31A2、52F9)、FMC63(鼠源)CAR T和野生型T细胞分别以不同比例与1×104的肿瘤细胞混合，加入到96孔U型板中，每组设3个复孔，并设单独加肿瘤细胞组作为阳性对照，250g离心5min后，置于37度5％CO2培养箱共培养18h；
(2)荧光素酶(Luciferase)定量杀伤效率检测：CAR T细胞与肿瘤细胞共培养或肿瘤细胞单独培养后18小时，在96孔细胞培养板中加入100μl/孔的荧光素酶底物(1×)，将细胞重悬混匀，立即通过多功能酶标仪测定RLU(relative light unit)，测定时间设为1秒。杀伤比例计算公式：100％×(对照孔读数-实验孔读数)/对照孔读数(不加细胞的空白组读数可以忽略)；
体外比较抗CD19完全人源化CAR T(不同SCFV序列的)、FMC63CAR T和野生型T细胞对表达CD19抗原的肿瘤细胞的识别杀伤功能时，肿瘤细胞选用RAJI-GL细胞系和NALM6-GL(荧光素酶基因Luciferase)，结果如图8-11所示；结果显示，与GFP-T野生型T细胞相比，表达11H8，15F2，17B6，27F11，31A2ScFv的CAR-T细胞对CD19阳性靶细胞具有较强的体外识别和杀伤能力，且杀伤水平基本不低于鼠源FMC63ScFv CAR-T细胞。
体外比较抗CD19完全人源化CAR T(不同SCFV序列的)、FMC63CAR T和野生型T细胞对不表达CD19抗原的肿瘤细胞的识别杀伤功能(CAR T细胞安全性试验)时，肿瘤细胞选用不表达CD19抗原的急性髓系白血病细胞系AML3，肺癌细胞系A549-GL、H460-GL，胃癌细胞系MKN28，SNU1，肝癌细胞系SMMC和HepG2，结果如图12-20所示；结果显示，与GFP-T野生型T细胞相比，表达抗CD19完全人源化ScFv的CAR-T细胞对测试的CD19阴性靶细胞基本不具有特异性识别和杀伤作用。
综上所述，本申请中的CD19抗原识别结合结构域经过人源化改造，不影响其对肿瘤细胞靶点抗原的识别能力，同时可能降低异种免疫排斥的发生概率，从而提升CAR-T细胞在人体中的持续时间，增强其对肿瘤细胞的免疫监控能力，降低肿瘤复发率，患者完全缓解期也可相应延长。
申请人声明，本发明通过上述实施例来说明本发明的产品、用途及其使用方式，但本发明并不局限于上述详细用途和使用方式，即不意味着本发明必须依赖上述详细用途和使用方式才能实施。所属技术领域的技术人员应该明了，对本发明的任何改进，对本发明产品各原料的等效替换及辅助成分的添加、具体方式的选择等，均落在本发明的保护范围和公开范围之内。
SEQUENCE LISTING
<110> 广东昭泰体内生物医药科技有限公司
<120> 一种嵌合抗原受体及其应用
<130> 2019
<160> 12
<170> PatentIn version 3.3
<210> 1
<211> 133
<212> PRT
<213> 人工合成序列
<400> 1
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg His
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Trp Tyr Asp Gly Ser Asn Gln Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Asp
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Arg Ser Ile Thr Trp Tyr Gly Gly Phe Asp Ile Trp Gly Gln
100 105 110
Gly Thr Met Val Thr Val Ser Ser Ala Gln Thr Thr Ala Pro Ser Val
115 120 125
Tyr Pro Leu Ala Pro
130
<210> 2
<211> 133
<212> PRT
<213> 人工合成序列
<400> 2
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Arg His
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Phe Tyr Asp Gly Ser Gln Asn Tyr Tyr Ala Asp Ser Val
50 55 60
Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Ser
65 70 75 80
Leu Gln Met Asp Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Arg Ser Ile Thr Trp Asn Gly Gly Phe Asp Ile Trp Gly Gln
100 105 110
Gly Thr Met Val Thr Val Ser Pro Ala Gln Thr Thr Ala Pro Ser Val
115 120 125
Tyr Pro Leu Ala Pro
130
<210> 3
<211> 133
<212> PRT
<213> 人工合成序列
<400> 3
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg His
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Asp
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Arg Ser Ile Thr Trp Asp Gly Ala Phe Asp Ile Trp Gly Gln
100 105 110
Gly Thr Met Val Thr Val Ser Ser Ala Gln Thr Thr Ala Pro Ser Val
115 120 125
Tyr Pro Leu Ala Pro
130
<210> 4
<211> 133
<212> PRT
<213> 人工合成序列
<400> 4
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg His
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Tyr Tyr Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Asp
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Arg Ser Ile Thr Trp Asn Gly Ala Phe Asp Ile Trp Gly Gln
100 105 110
Gly Thr Met Val Thr Val Ser Ser Ala Gln Thr Thr Ala Pro Ser Val
115 120 125
Tyr Pro Leu Ala Pro
130
<210> 5
<211> 133
<212> PRT
<213> 人工合成序列
<400> 5
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg His
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Asp
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Arg Ser Ile Thr Trp Asp Gly Ala Phe Asp Ile Trp Gly Gln
100 105 110
Gly Thr Met Val Thr Val Ser Ser Ala Gln Thr Thr Ala Pro Ser Val
115 120 125
Tyr Pro Leu Ala Pro
130
<210> 6
<211> 138
<212> PRT
<213> 人工合成序列
<400> 6
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Ala Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30
Gly Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Val Ile Trp His Asp Gly Ser Ile Lys Asn Tyr Ala Asp Phe Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu Asp Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Gln Gly Asn Tyr Tyr Gly Trp Gly Ser Tyr Lys Ala Phe
100 105 110
Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Gln Thr
115 120 125
Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro
130 135
<210> 7
<211> 106
<212> PRT
<213> 人工合成序列
<400> 7
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Pro Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Ala Tyr Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 8
<211> 106
<212> PRT
<213> 人工合成序列
<400> 8
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ala Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Arg Phe Tyr Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 9
<211> 106
<212> PRT
<213> 人工合成序列
<400> 9
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Ala Tyr Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 10
<211> 106
<212> PRT
<213> 人工合成序列
<400> 10
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Ala Tyr Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 11
<211> 106
<212> PRT
<213> 人工合成序列
<400> 11
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Val Thr Cys Arg Ala Ser Gln Ser Ile Arg Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Ala Tyr Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 12
<211> 107
<212> PRT
<213> 人工合成序列
<400> 12
Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Val Phe Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Glu Leu Leu Leu
35 40 45
Tyr Ala Thr Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Leu Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Leu Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Val Tyr Ser Phe Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
Claims (10)
1.一种嵌合抗原受体，其特征在于，其包含至少一个胞外结构域、任选的跨膜结构域和至少一个胞内共刺激信号传导结构域，其中，所述胞外结构域包含CD19抗原识别结合结构域；
其中，所述CD19抗原识别结合结构域包含具有如SEQ ID NO.1-6之一所示的序列的重链可变区或与其具有至少85％序列同一性的变体；
所述CD19抗原识别结合结构域包含具有如SEQ ID NO.7-12之一所示的序列的轻链可变区或与其具有至少85％序列同一性的变体。
2.根据权利要求1所述的嵌合抗原受体，其特征在于，所述CD19抗原识别结合结构域包含与SEQ ID NO.1-6之一所示的序列具有至少90％，优选95％序列同一性的变体的重链可变区；
优选地，所述CD19抗原识别结合结构域包含与SEQ ID NO.7-12之一所示的序列具有至少90％，优选95％序列同一性的变体的轻链可变区。
3.根据权利要求1或2所述的嵌合抗原受体，其特征在于，所述CD19抗原识别结合结构域包含具有如SEQ ID NO.1-6之一所示的序列的重链可变区或与其具有至少85％，优选90％，进一步优选95％序列同一性的变体；
优选地，所述CD19抗原识别结合结构域包含具有如SEQ ID NO.7-12之一所示的序列的轻链可变区或与其具有至少85％，优选90％，进一步优选95％序列同一性的变体。
4.根据权利要求1-3中任一项所述的嵌合抗原受体，其特征在于，所述嵌合抗原受体的胞外结构域还包括任选的信号肽结构域；
优选地，所述信号肽结构域为GM-CSF信号肽、IL-2信号肽或CD8α信号肽中的任意一种。
5.根据权利要求1-4中任一项所述的嵌合抗原受体，其特征在于，所述胞内结构域还包括胞内共刺激信号传导域和/或CD3ζ信号传导域；
优选地，所述胞内共刺激信号传导域包括人CD28胞内区、人4-1BB胞内区、人TLR1胞内区、人TLR2胞内区、人TLR3胞内区、人TLR4胞内区、人TLR5胞内区、人TLR6胞内区、人TLR7胞内区、人TLR8胞内区、人TLR9胞内区、人TLR10胞内区、人DAP10胞内区、人CD27胞内区、人OX40胞内区、人CD30胞内区、人CD40胞内区、人PD-1胞内区、人CTLA-4胞内区、人TIM3胞内区、人LAG3胞内区、人TGFβ胞内区、人ICOS胞内区、人淋巴细胞功能相关抗原1胞内区、人CD2胞内区、人CD7胞内区、人LIGHT胞内区、人NKG2C胞内区、人NKG2D胞内区、人NKp46胞内区、人NKp30胞内区、人NKp44胞内区、人DNAM1胞内区、人B7-H3胞内区或人CD83胞内区中的任意一种或至少两种的组合，优选为人CD28胞内区、人4-1BB胞内区、人TLR2胞内区、人DAP10胞内区×3、人DAP10胞内区×6或人DAP10胞内区×9中的任意一种或至少两种的组合；
优选地，所述跨膜结构域还包括任选的跨膜结构域，优选为CD3、CD8、CD28、OX40或ICOS中的任意一种或至少两种的组合，进一步优选为CD28。
6.编码如权利要求1-7任一项所述的嵌合抗原受体的核酸。
7.一种嵌合抗原受体表达细胞，其中引入了如权利要求6所述的核酸；
优选地，所述细胞为T细胞或含有T细胞的细胞群。
8.制备如权利要求7所述的嵌合抗原受体表达细胞的方法，其包括将如权利要求6所述的核酸引入细胞的步骤；
优选地，所述细胞为T细胞或含有T细胞的细胞群。
9.如权利要求1-7任一项所述的嵌合抗原受体、如权利要求6所述的核酸或如权利要求7所述的嵌合抗原受体表达细胞在制备治疗肿瘤的药物中的用途；
优选地，所述肿瘤为CD19阳性恶性肿瘤和/或B细胞恶性肿瘤。
10.一种治疗肿瘤的药物组合，其特征在于，包括如权利要求1-7任一项所述的嵌合抗原受体、如权利要求6所述的核酸或如权利要求7所述的嵌合抗原受体表达细胞中的任意一种或至少两种的组合；
优选地，所述药物组合还包括免疫治疗药物和/或小分子化学药物。
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910081590.8A CN109734813B (zh) | 2019-01-28 | 2019-01-28 | 一种嵌合抗原受体及其应用 |
| EP19897536.9A EP3715373A4 (en) | 2019-01-28 | 2019-03-08 | NEW SEQUENCE OF AMINO ACIDS SCFV, CHEMICAL ANTIGENIC RECEPTOR INCLUDING IT AND ASSOCIATED USE |
| US16/957,647 US11713348B2 (en) | 2019-01-28 | 2019-03-08 | ScFv amino acid sequence, chimeric antigen receptor containing same and application thereof |
| AU2019400152A AU2019400152B2 (en) | 2019-01-28 | 2019-03-08 | Novel scFv amino acid sequence, chimeric antigen receptor containing same and application thereof |
| PCT/CN2019/077492 WO2020155310A1 (zh) | 2019-01-28 | 2019-03-08 | 一种新型scFv氨基酸序列、包含其的嵌合抗原受体及其应用 |
| JP2020513619A JP7091447B2 (ja) | 2019-01-28 | 2019-03-08 | 新型なｓｃＦｖアミノ酸配列、それを含むキメラ抗原受容体、およびその使用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910081590.8A CN109734813B (zh) | 2019-01-28 | 2019-01-28 | 一种嵌合抗原受体及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109734813A true CN109734813A (zh) | 2019-05-10 |
| CN109734813B CN109734813B (zh) | 2022-06-17 |
Family
ID=66366402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910081590.8A Active CN109734813B (zh) | 2019-01-28 | 2019-01-28 | 一种嵌合抗原受体及其应用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11713348B2 (zh) |
| EP (1) | EP3715373A4 (zh) |
| JP (1) | JP7091447B2 (zh) |
| CN (1) | CN109734813B (zh) |
| AU (1) | AU2019400152B2 (zh) |
| WO (1) | WO2020155310A1 (zh) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111748044A (zh) * | 2020-07-31 | 2020-10-09 | 广东昭泰体内生物医药科技有限公司 | Cd19和pd-l1双靶点嵌合抗原受体及其应用 |
| CN111808200A (zh) * | 2020-07-16 | 2020-10-23 | 广东昭泰体内生物医药科技有限公司 | Cd19和cd22双靶点嵌合抗原受体及其应用 |
| CN111848822A (zh) * | 2020-07-31 | 2020-10-30 | 广东昭泰体内生物医药科技有限公司 | Cd19和cd30双靶点嵌合抗原受体及其应用 |
| CN111848820A (zh) * | 2020-07-31 | 2020-10-30 | 广东昭泰体内生物医药科技有限公司 | Cd19和bcma双靶点嵌合抗原受体及其应用 |
| CN111848819A (zh) * | 2020-07-31 | 2020-10-30 | 广东昭泰体内生物医药科技有限公司 | 一种靶向msln的嵌合抗原受体及其应用 |
| CN111875710A (zh) * | 2020-07-31 | 2020-11-03 | 广东昭泰体内生物医药科技有限公司 | 异质性肿瘤治疗用免疫细胞及其应用 |
| CN112029729A (zh) * | 2020-09-09 | 2020-12-04 | 广东昭泰体内生物医药科技有限公司 | Cd19和cd22双靶点嵌合抗原受体nk细胞及其应用 |
| CN112048481A (zh) * | 2020-09-09 | 2020-12-08 | 广东昭泰体内生物医药科技有限公司 | 一种靶向cd19的嵌合抗原受体nk细胞及其应用 |
| CN112195157A (zh) * | 2020-10-12 | 2021-01-08 | 广东昭泰体内生物医药科技有限公司 | Cd19和cd22双靶点嵌合抗原受体t细胞及其应用 |
| WO2021027795A1 (en) * | 2019-08-12 | 2021-02-18 | Sunshine Lake Pharma Co., Ltd. | Chimeric antigen receptors and uses thereof |
| CN112661827A (zh) * | 2021-01-15 | 2021-04-16 | 武汉大学 | 一种桥接整合因子1的抗原肽及其抗体与应用 |
| CN115297873A (zh) * | 2019-11-08 | 2022-11-04 | 梅约医学教育与研究基金会 | 利用工程化改造的间充质干细胞治疗炎症和退行性疾病的方法和物质 |
| CN116836299A (zh) * | 2023-06-09 | 2023-10-03 | 上海恩凯细胞技术有限公司 | 嵌合抗原受体及其应用 |
| CN117467022A (zh) * | 2023-09-28 | 2024-01-30 | 上海恩凯细胞技术有限公司 | 嵌合抗原受体及其应用 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022153698A1 (ja) * | 2021-01-15 | 2022-07-21 | 国立大学法人東海国立大学機構 | キメラ標的因子受容体 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013169691A1 (en) * | 2012-05-07 | 2013-11-14 | Trustees Of Dartmouth College | Anti-b7-h6 antibody, fusion proteins, and methods of using the same |
| US20140242701A1 (en) * | 2011-10-07 | 2014-08-28 | Takara Bio Inc. | Chimeric antigen receptor |
| CN105158466A (zh) * | 2015-05-05 | 2015-12-16 | 中国科学院广州生物医药与健康研究院 | 一种检测抗cd19的嵌合抗原受体t细胞对白血病细胞抑制作用的方法 |
| CN106749675A (zh) * | 2016-12-27 | 2017-05-31 | 深圳市体内生物医药科技有限公司 | 一种重组慢病毒及其应用 |
| US20170159025A1 (en) * | 2014-05-14 | 2017-06-08 | Carsgen Therapeutics Limited | Nucleic acid for coding chimeric antigen receptor protein and t lymphocyte for expression of chimeric antigen receptor protein |
| CN107207613A (zh) * | 2015-08-07 | 2017-09-26 | 深圳市体内生物医药科技有限公司 | 含Toll样受体胞内结构域的嵌合抗原受体 |
| CN108383914A (zh) * | 2018-02-23 | 2018-08-10 | 北京美康基免生物科技有限公司 | 一种基于cd19的嵌合抗原受体及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005012493A2 (en) | 2003-07-31 | 2005-02-10 | Immunomedics, Inc. | Anti-cd19 antibodies |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| AU2015270912B9 (en) | 2014-06-02 | 2021-01-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting CD-19 |
| TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對ｃｄ１９具專一性之抗體及嵌合抗原受體 |
| CA2968357A1 (en) * | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
| GB201503742D0 (en) * | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| US10493139B2 (en) * | 2015-07-24 | 2019-12-03 | Innovative Cellular Therapeutics CO., LTD. | Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor |
| WO2018126369A1 (en) | 2017-01-05 | 2018-07-12 | Shanghai Sidansai Biotechnology Co., Ltd | Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor |
| CN106699888B (zh) | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | 一种pd-1抗体及其制备方法和应用 |
| CN114470193B (zh) | 2015-10-13 | 2024-08-30 | 优瑞科生物技术公司 | 对人类cd19具有专一性的抗体药剂和其用途 |
| US20200377606A1 (en) | 2016-04-18 | 2020-12-03 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
| CN106220736B (zh) * | 2016-07-20 | 2020-01-10 | 深圳市体内生物医药科技有限公司 | 一种嵌合抗原受体、表达其的细胞及其制备方法和用途 |
| CN108070607B (zh) * | 2016-11-10 | 2020-12-08 | 上海恒润达生生物科技有限公司 | 靶向CD19-41BB-tEGFR的嵌合抗原受体及其用途 |
| JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
| CN107226867B (zh) | 2017-07-25 | 2018-02-06 | 重庆精准生物技术有限公司 | 抗人cd19抗原的嵌合抗原受体及其应用 |
| CN107312091B (zh) * | 2017-05-02 | 2019-10-22 | 重庆精准生物技术有限公司 | 靶向人cd19抗原的人源化单克隆抗体 |
| CN107383196B (zh) | 2017-08-30 | 2019-12-17 | 广州百暨基因科技有限公司 | 人源化抗cd19的抗原结合片段 |
-
2019
- 2019-01-28 CN CN201910081590.8A patent/CN109734813B/zh active Active
- 2019-03-08 EP EP19897536.9A patent/EP3715373A4/en active Pending
- 2019-03-08 JP JP2020513619A patent/JP7091447B2/ja active Active
- 2019-03-08 AU AU2019400152A patent/AU2019400152B2/en active Active
- 2019-03-08 US US16/957,647 patent/US11713348B2/en active Active
- 2019-03-08 WO PCT/CN2019/077492 patent/WO2020155310A1/zh unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140242701A1 (en) * | 2011-10-07 | 2014-08-28 | Takara Bio Inc. | Chimeric antigen receptor |
| WO2013169691A1 (en) * | 2012-05-07 | 2013-11-14 | Trustees Of Dartmouth College | Anti-b7-h6 antibody, fusion proteins, and methods of using the same |
| US20170159025A1 (en) * | 2014-05-14 | 2017-06-08 | Carsgen Therapeutics Limited | Nucleic acid for coding chimeric antigen receptor protein and t lymphocyte for expression of chimeric antigen receptor protein |
| CN105158466A (zh) * | 2015-05-05 | 2015-12-16 | 中国科学院广州生物医药与健康研究院 | 一种检测抗cd19的嵌合抗原受体t细胞对白血病细胞抑制作用的方法 |
| CN107207613A (zh) * | 2015-08-07 | 2017-09-26 | 深圳市体内生物医药科技有限公司 | 含Toll样受体胞内结构域的嵌合抗原受体 |
| CN106749675A (zh) * | 2016-12-27 | 2017-05-31 | 深圳市体内生物医药科技有限公司 | 一种重组慢病毒及其应用 |
| CN108383914A (zh) * | 2018-02-23 | 2018-08-10 | 北京美康基免生物科技有限公司 | 一种基于cd19的嵌合抗原受体及其应用 |
Non-Patent Citations (5)
| Title |
|---|
| JENA, BIPULENDU ET AL: "Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials", 《PLOS ONE》 * |
| JENA, BIPULENDU ET AL: "Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials", 《PLOS ONE》, vol. 8, no. 3, 1 March 2013 (2013-03-01), pages 1 - 12 * |
| 倪芳等: "嵌合抗原受体T细胞在B细胞淋巴瘤中的应用进展", 《中国细胞生物学学报》 * |
| 倪芳等: "嵌合抗原受体T细胞在B细胞淋巴瘤中的应用进展", 《中国细胞生物学学报》, vol. 40, no. 1, 16 January 2019 (2019-01-16), pages 2260 - 2268 * |
| 李欢欢等: "应用CD19修饰的嵌合抗原受体T细胞治疗淋巴细胞白血病", 《中国实验血液学杂志》, vol. 22, no. 06, 20 December 2014 (2014-12-20), pages 1753 - 11756 * |
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021027795A1 (en) * | 2019-08-12 | 2021-02-18 | Sunshine Lake Pharma Co., Ltd. | Chimeric antigen receptors and uses thereof |
| CN112390894A (zh) * | 2019-08-12 | 2021-02-23 | 广东东阳光药业有限公司 | 嵌合抗原受体及其应用 |
| CN115297873A (zh) * | 2019-11-08 | 2022-11-04 | 梅约医学教育与研究基金会 | 利用工程化改造的间充质干细胞治疗炎症和退行性疾病的方法和物质 |
| CN111808200A (zh) * | 2020-07-16 | 2020-10-23 | 广东昭泰体内生物医药科技有限公司 | Cd19和cd22双靶点嵌合抗原受体及其应用 |
| WO2022011846A1 (zh) * | 2020-07-16 | 2022-01-20 | 广东昭泰体内生物医药科技有限公司 | Cd19和cd22双靶点嵌合抗原受体及其应用 |
| CN111875710A (zh) * | 2020-07-31 | 2020-11-03 | 广东昭泰体内生物医药科技有限公司 | 异质性肿瘤治疗用免疫细胞及其应用 |
| CN111748044B (zh) * | 2020-07-31 | 2022-02-18 | 广东昭泰体内生物医药科技有限公司 | Cd19和pd-l1双靶点嵌合抗原受体及其应用 |
| CN111848822A (zh) * | 2020-07-31 | 2020-10-30 | 广东昭泰体内生物医药科技有限公司 | Cd19和cd30双靶点嵌合抗原受体及其应用 |
| CN111848822B (zh) * | 2020-07-31 | 2022-02-15 | 广东昭泰体内生物医药科技有限公司 | Cd19和cd30双靶点嵌合抗原受体及其应用 |
| CN111748044A (zh) * | 2020-07-31 | 2020-10-09 | 广东昭泰体内生物医药科技有限公司 | Cd19和pd-l1双靶点嵌合抗原受体及其应用 |
| CN111848819A (zh) * | 2020-07-31 | 2020-10-30 | 广东昭泰体内生物医药科技有限公司 | 一种靶向msln的嵌合抗原受体及其应用 |
| CN111848820A (zh) * | 2020-07-31 | 2020-10-30 | 广东昭泰体内生物医药科技有限公司 | Cd19和bcma双靶点嵌合抗原受体及其应用 |
| CN112029729A (zh) * | 2020-09-09 | 2020-12-04 | 广东昭泰体内生物医药科技有限公司 | Cd19和cd22双靶点嵌合抗原受体nk细胞及其应用 |
| CN112048481A (zh) * | 2020-09-09 | 2020-12-08 | 广东昭泰体内生物医药科技有限公司 | 一种靶向cd19的嵌合抗原受体nk细胞及其应用 |
| CN112029729B (zh) * | 2020-09-09 | 2023-03-31 | 广东昭泰体内生物医药科技有限公司 | Cd19和cd22双靶点嵌合抗原受体nk细胞及其应用 |
| CN112195157A (zh) * | 2020-10-12 | 2021-01-08 | 广东昭泰体内生物医药科技有限公司 | Cd19和cd22双靶点嵌合抗原受体t细胞及其应用 |
| CN112195157B (zh) * | 2020-10-12 | 2023-03-31 | 汤朝阳 | Cd19和cd22双靶点嵌合抗原受体t细胞及其应用 |
| CN112661827A (zh) * | 2021-01-15 | 2021-04-16 | 武汉大学 | 一种桥接整合因子1的抗原肽及其抗体与应用 |
| CN112661827B (zh) * | 2021-01-15 | 2022-04-01 | 武汉大学 | 一种桥接整合因子1的抗原肽及其抗体与应用 |
| CN116836299A (zh) * | 2023-06-09 | 2023-10-03 | 上海恩凯细胞技术有限公司 | 嵌合抗原受体及其应用 |
| CN116836299B (zh) * | 2023-06-09 | 2024-07-09 | 上海恩凯细胞技术有限公司 | 嵌合抗原受体及其应用 |
| CN117467022A (zh) * | 2023-09-28 | 2024-01-30 | 上海恩凯细胞技术有限公司 | 嵌合抗原受体及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US11713348B2 (en) | 2023-08-01 |
| EP3715373A4 (en) | 2021-08-25 |
| AU2019400152B2 (en) | 2022-04-28 |
| EP3715373A1 (en) | 2020-09-30 |
| CN109734813B (zh) | 2022-06-17 |
| WO2020155310A1 (zh) | 2020-08-06 |
| US20210238253A1 (en) | 2021-08-05 |
| JP7091447B2 (ja) | 2022-06-27 |
| JP2021514930A (ja) | 2021-06-17 |
| AU2019400152A1 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109734813A (zh) | 一种嵌合抗原受体及其应用 | |
| US11897967B2 (en) | Humanized anti-MUC1* antibodies | |
| CN107880128B (zh) | 一种抗cd19的全人源抗体或抗体片段及其方法和应用 | |
| CN109153731A (zh) | 靶向bcma的嵌合抗原受体及其使用方法 | |
| CN109942709B (zh) | 一种抗bcma的单域抗体及其应用 | |
| CN106939047A (zh) | 一种pd-l1抗体及其制备方法 | |
| CN108373504A (zh) | Cd24特异性抗体和抗cd24-car-t细胞 | |
| CN113480650B (zh) | 一种全人源靶向cd276的car-t细胞的制备方法及应用 | |
| US20240141038A1 (en) | Antibody against nkp46 and application thereof | |
| CN110655581B (zh) | 一种抗癌胚抗原的抗体及其制备方法和用途 | |
| CN110713539A (zh) | 一种抗癌胚抗原的抗体及其制备方法和用途 | |
| WO2022247804A1 (zh) | 抗gprc5d抗体、其制备方法与用途 | |
| CN109970859A (zh) | Glypican-3特异性抗体及其特异性CAR-T细胞 | |
| CN115279792A (zh) | 对bcma特异的抗体及嵌合抗原受体 | |
| CN115785269B (zh) | 抗pd-l1的抗体及其应用 | |
| CN118359728A (zh) | 靶向gpc3的嵌合抗原受体及其应用 | |
| CN118234751A (zh) | 免疫反应性分子及其用途 | |
| KR20220122844A (ko) | Cd22에 특이적인 인간화 항체 및 이의 용도 | |
| CN117285628A (zh) | 抗vista抗体及其应用 | |
| KR20210148823A (ko) | Cd22에 특이적인 항체 및 이의 용도 | |
| CN117186235A (zh) | 抗4-1BB/抗EGFRvⅢ的双特异抗体及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |